ArticleFood and waterborne parasitology2019
Diagnostic and follow-up performance of serological tests for different forms/courses of alveolar echinococcosis.
Article in Food and waterborne parasitology, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 27 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
27 citing papers in PubMed.
- Alveolar echinococcosis.Current opinion in infectious diseases · 2026Review
- Conserved surface-exposed linear epitopes of Echinococcus multilocularis thioredoxin peroxidase enable non-invasive diagnosis of alveolar echinococcosis in intermediate host.PLoS neglected tropical diseases · 2026Article
- Equine alveolar echinococcosis: a focus on epidemiology, clinical and pathological features, and diagnostics.Journal of equine science · 2026Review
- Postoperative CT-derived spleen volumetry for recurrence risk stratification after curative-intent surgery for hepatic alveolar echinococcosis.Infection · 2026Article
- Hepatic alveolar echinococcosis mimicking cholangiocarcinoma: a case study.BMC infectious diseases · 2026Article
- The Role of Innate Lymphoid Cells in the Pathogenesis of Hepatic Echinococcosis: A Literature Review.Parasite immunology · 2026Review
- Epidemiological and clinical characteristics of patients in the alveolar echinococcosis registry, France, 1982 to 2021.Euro surveillance : bulletin Europeen sur les maladies transmissibles = European communicable disease bulletin · 2025Article
- The initial stage of alveolar echinococcosis is a diagnostic challenge: a case report.Journal of medical case reports · 2025Article
- Advances in Novel Diagnostic Techniques for Alveolar Echinococcosis.Diagnostics (Basel, Switzerland) · 2025Review
- Identification and characterization of the elusive protein backbone of the immuno-dominant and species-specific Em2(G11) metacestode antigen ofFrontiers in parasitology · 2025Article
- Serological Comparison of Native Antigen ELISAs with Rapid ICT Test Kits for the Diagnosis of Human Alveolar and Cystic Echinococcosis in China.Tropical medicine and infectious disease · 2024Article
- Chemotherapy for the treatment of alveolar echinococcosis: Where are we?Parasite (Paris, France) · 2024Review
- Bacterial Infection of an Alveolar Echinococcus Cyst fromMedicina (Kaunas, Lithuania) · 2023Review
- Report of a Case with Intraventricular Cardiac Hydatid Cyst with Coronary Artery Disease and Multiple Hepatic Hydatid Cysts.Advanced biomedical research · 2023Article
- Monoclonal antibody-based localization of major diagnostic antigens in metacestode tissue, excretory/secretory products, and extracellular vesicles ofFrontiers in cellular and infection microbiology · 2023Article
- Alveolar echinococcosis in solid organ transplant recipients: a case series from two national cohorts.Parasite (Paris, France) · 2023Article
- Laparoscopic resection of hepatic alveolar echinococcosis: A single-center experience.PLoS neglected tropical diseases · 2022Article
- Stage-Oriented CT Classification and Intermodal Evolution Model in Hepatic Alveolar Echinococcosis.RoFo : Fortschritte auf dem Gebiete der Rontgenstrahlen und der Nuklearmedizin · 2022Article
- Serological Assays for Alveolar and Cystic Echinococcosis-A Comparative Multi-Test Study in Switzerland and Kyrgyzstan.Pathogens (Basel, Switzerland) · 2022Article
- Evaluation of Eosinophilic Cationic Protein as a Marker of Alveolar and Cystic Echinococcosis.Pathogens (Basel, Switzerland) · 2022Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Diagnosis of alveolar echinococcosis (AE) is predominantly based on imaging procedures combined with immunodiagnostic testing. In the present study, we retrospectively analyzed the performance of four serological tests (EgHF-ELISA, Em2-ELISA, recEm18-ELISA and Em-Immunoblotting) for initial diagnosis and subsequent monitoring of AE patients. Overall, 101 AE patients were included, grouped according to treatment options and immune status as follows: (A) curative surgical treatment (n = 45 patients), (B) non-radical or palliative surgical treatment (n = 11), (C) benzimidazoles only (n = 20), (D) immunocompromised with radical surgical treatment (n = 11), (E) immunocompromised with benzimidazoles only (n = 4), and finally a group of 10 AE patients (F) that were considered to present so-called "abortive" lesions. Initial (i.e. pretreatment) ELISA-based diagnosis for patients in groups A to E revealed overall diagnostic sensitivities of 95% for EgHF, 86% for Em2, and 80% for recEm18, respectively. Comparatively, the diagnostic sensitivity of Em-Immunoblotting was higher with an overall value of 98%. In group F, only Em-Immunoblotting had an excellent diagnostic sensitivity (100%), whereas the ELISAs had poor sensitivities of 30% (EgHF- and Em2-ELISA) or even 0% (recEm18-ELISA). Serological monitoring of AE patients showed a clear association between a curative development of disease (induced either by surgery or benzimidazole medication) and a negativization in the ELISAs. This effect was most pronounced for the recEm18-ELISA, where 56% negativized following diagnosis/treatment, as compared to 36% for the EgHF-ELISA, and 37% for the Em2-ELISA, respectively. After radical surgery, the mean time until negativization in the recEm18-ELISA was 2.4 years (SD 1.6). This was significantly shorter than the mean 3.9 years (SD 2.5) in those AE patients with non-radical, palliative surgery or ABZ treatment who were able to negativize during the study period (
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.